Alwin Capital

Bio-Link is a drug development company founded in 2001 and headquartered in Shanghai, China. It specializes in providing bioprocessing solutions for the life science industry, including the development and manufacturing of key process equipment and consumables. Bio-Link's offerings include technologies for vaccines, antibody drugs, cell therapy, gene therapy, and various biologics. The company focuses on upstream cell culture, disposable dispensing reservoirs, and downstream processes such as chromatography and ultrafiltration. By delivering innovative products and services, Bio-Link aims to enhance the efficiency, safety, and competitiveness of the biopharmaceutical supply chain. Additionally, the company explores wearable technology solutions for elderly care, further diversifying its portfolio.

Sigma Squares Tech is a developer of automated manufacturing systems that focuses on industrial automation and computer vision solutions. The company specializes in creating cloud-based vision service platforms and algorithms designed to detect and analyze substantial volumes of industrial data during the manufacturing process. By offering integrated analytical and control solutions, Sigma Squares Tech aims to enhance operational efficiency for small and medium-sized manufacturing companies, enabling them to leverage advanced technology for improved productivity and decision-making.

ICE Bioscience Inc. is a contract research organization based in Beijing, China, specializing in preclinical research solutions for electrophysiology and drug discovery. Founded in 2010, the company focuses on the development of ion channel-related drugs, particularly targeting the nervous and cardiovascular systems. ICE Bioscience offers a range of services, including ion channel screening, cardiac safety panels, and molecular biology, utilizing proprietary cell lines for voltage-gated and ligand-gated ion channels. The company is also dedicated to expanding its capabilities in immunology, oncology, and other areas, providing comprehensive support for target validation and preclinical candidate identification. Through its advanced screening platforms and flexible collaboration models, ICE Bioscience aims to enhance the efficiency of the drug discovery process for various clinical needs.

Immupeutics Medical Technology Co., Ltd. is a biomedical research company specializing in tumor immunotherapy. The firm is dedicated to the research and development of immune cell therapy drugs targeting various types of tumors. In addition to its primary focus on therapeutic agents, Immupeutics also invests in companion diagnostic technology and immunological multi-omics technology. By integrating these innovative approaches, the company aims to enhance patient outcomes through the provision of advanced immune cell therapies and comprehensive treatment methodologies.

Sonosemi Medical is a provider of medical devices that specializes in the development of pan-vascular active interventional products, diagnosis, and treatment solutions.

ICE Bioscience Inc. is a contract research organization based in Beijing, China, specializing in preclinical research solutions for electrophysiology and drug discovery. Founded in 2010, the company focuses on the development of ion channel-related drugs, particularly targeting the nervous and cardiovascular systems. ICE Bioscience offers a range of services, including ion channel screening, cardiac safety panels, and molecular biology, utilizing proprietary cell lines for voltage-gated and ligand-gated ion channels. The company is also dedicated to expanding its capabilities in immunology, oncology, and other areas, providing comprehensive support for target validation and preclinical candidate identification. Through its advanced screening platforms and flexible collaboration models, ICE Bioscience aims to enhance the efficiency of the drug discovery process for various clinical needs.

Reforgene Medicine is a biomedical company focused on developing innovative drugs aimed at curing genetic diseases, chronic illnesses, and cancer. Utilizing advanced gene editing and genomic technologies, the company creates programmable medicine that offers targeted treatments for patients. By harnessing the potential of genome editing, Reforgene Medicine seeks to improve patient outcomes and contribute to the advancement of personalized healthcare solutions.

Primont is a researcher and producer of surgical instruments and equipment. They offer medically absorbable synthetic sutures, absorbable knot free sutures, non-absorbable surgical sutures, and non absorbable self sealing surgical sutures.

Neukio Biotherapeutics is a biopharmaceutical company dedicated to the development of immune cell therapies aimed at treating cancer. The company specializes in the research, development, and industrialization of allogenic immune cell drugs, particularly focusing on iPSC-CAR-NK cell products. By leveraging a combination of in-house innovation and strategic collaborations with leading partners, Neukio Biotherapeutics aims to provide effective therapeutic options for cancer patients globally. Their commitment to advancing oncology treatments positions them as a significant player in the field of immunotherapy.

Aibo Medical Robot was established in Shenzhen in June 2020, focusing on the vascular interventional surgery robot market. It is reported that behind this "new" company is the accumulation of years of scientific research and technology - that is , the nearly 30 years of research and development accumulation of the founding team.

Rotex Tech is a technology company specializing in the development of bioelectric flexible sensor technology, primarily through its innovative electronic tattoos. These ultra-thin and flexible devices are designed to adhere to skin and other soft surfaces, significantly enhancing the functionality of medical wearables and therapeutic products. Rotex Tech's solutions cater to various sectors, including healthcare and fitness, as well as human-computer interaction (HCI), aiming to improve user experience and health monitoring.

Immupeutics Medical Technology Co., Ltd. is a biomedical research company specializing in tumor immunotherapy. The firm is dedicated to the research and development of immune cell therapy drugs targeting various types of tumors. In addition to its primary focus on therapeutic agents, Immupeutics also invests in companion diagnostic technology and immunological multi-omics technology. By integrating these innovative approaches, the company aims to enhance patient outcomes through the provision of advanced immune cell therapies and comprehensive treatment methodologies.

Sanegene Bio is a biotechnology company focused on developing RNA interference (RNAi) therapeutics aimed at addressing unmet clinical needs across various therapeutic areas. Its innovative RNAi drug discovery platform targets disease-causing genes, effectively knocking them down to provide potential treatments for conditions such as cardiovascular and metabolic diseases, immunology-related disorders, and diseases affecting the nervous system. By leveraging advanced RNA technology, Sanegene Bio is capable of achieving specific delivery of multiple RNA drugs, enhancing the effectiveness of its therapeutic offerings for patients suffering from a range of health issues, including infectious diseases and eye conditions.

Meibai bio focuses on the R&D, production & sales of biological scaffold material for maxillofacial tissue regeneration for medical and medical plastic and cosmetic clinical needs.

EdiGene Inc. is a biotechnology company specializing in the development of genome editing technologies for therapeutic applications in cancer and various genetic diseases. Founded in 2015 and headquartered in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts, EdiGene focuses on both ex vivo and in vivo gene-editing therapies. The company has established proprietary platforms for editing hematopoietic stem cells and T cells, as well as an RNA base editing approach for in vivo applications. EdiGene's innovative methods enable targeted modifications of genetic information in human cells and facilitate high-throughput drug discovery through advanced screening techniques. By translating these technologies into novel therapeutics, EdiGene aims to improve the safety and efficacy of gene therapy, ultimately benefiting patients, the pharmaceutical industry, and the scientific research community.

Rosenbot provides medical robot technology and uses technological innovation to promote the reform of medical models. It is committed to creating a new generation of orthopedic surgery robot systems with intelligent fracture reduction functions, it is the first in the world to realize advanced technologies such as intraoperative real-time 3D navigation, assisted fracture reduction operation, automatic operation planning, etc. The intelligent surgical operation of the whole operation process meets the urgent needs of clinical treatment.

NeoCura is a biotechnology company based in Shenzhen, China, founded in 2017. It specializes in developing AI-based platforms and diagnostic tests aimed at enhancing cancer therapies. The company's offerings include NeoCura AI ALPINE, a platform for predicting tumor neoantigens, and NeoCura AI EVEREST, which validates these neoantigens to improve patient outcomes. Additionally, NeoCura TP serves as an intelligent companion diagnostic tool that forecasts treatment options for immunotherapy drugs, while NeoCura Ag focuses on patient-specific neoantigen immunotherapy. Alongside these platforms, NeoCura also provides diagnostics and medical laboratory services, leveraging AI to analyze molecular biology and clinical data to assist physicians in refining cancer diagnosis and treatment strategies.

Reforgene Medicine is a biomedical company focused on developing innovative drugs aimed at curing genetic diseases, chronic illnesses, and cancer. Utilizing advanced gene editing and genomic technologies, the company creates programmable medicine that offers targeted treatments for patients. By harnessing the potential of genome editing, Reforgene Medicine seeks to improve patient outcomes and contribute to the advancement of personalized healthcare solutions.

EdiGene Inc. is a biotechnology company specializing in the development of genome editing technologies for therapeutic applications in cancer and various genetic diseases. Founded in 2015 and headquartered in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts, EdiGene focuses on both ex vivo and in vivo gene-editing therapies. The company has established proprietary platforms for editing hematopoietic stem cells and T cells, as well as an RNA base editing approach for in vivo applications. EdiGene's innovative methods enable targeted modifications of genetic information in human cells and facilitate high-throughput drug discovery through advanced screening techniques. By translating these technologies into novel therapeutics, EdiGene aims to improve the safety and efficacy of gene therapy, ultimately benefiting patients, the pharmaceutical industry, and the scientific research community.

Xbiome Co. Ltd., established in 2017 and headquartered in Shenzhen, China, is an AI-based microbiome drug development company. It specializes in the analysis of patient and donor intestinal flora using artificial intelligence to accelerate the development of effective pharmaceuticals for microecological intestinal disorders. Xbiome's products focus on micro-ecological treatment, aiming to manage the gut health of a vast population.